This interview provides perspective on developments in breast cancer treatment in 2017, as well as a preview of what we can expect to change in the treatment of breast cancer in 2018.
Oncology Vol 31 No 12_Suppl_1
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves SC Pembrolizumab Formulation in Solid Tumors
2
Cevostamab Post-CAR T-Cell Therapy is Safe in Heavily Pretreated Multiple Myeloma
3
BPd Maintenance Safe, Yields Responses in High-Risk Multiple Myeloma
4
Eque-Cel Displays Favorable Long-Term Survival in R/R Multiple Myeloma
5
